Adverse events among 2408 unrelated donors of peripheral blood stem cells: Results of a prospective trial from the national marrow donor program

Blood

Volumn 113, Issue 15, 2009, Pages 3604-3611

  Pulsipher, Michael A ^a   Chitphakdithai, Pintip ^b   Miller, John P ^c   Logan, Brent R ^d   King, Roberta J ^b   Rizzo, J Douglas ^d   Leitman, Susan F ^e   Anderlini, Paolo ^f   Haagenson, Michael D ^b   Kurian, Seira ^g   Klein, John P ^d   Horowitz, Mary M ^d   Confer, Dennis L ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Center for International Blood and Marrow Transplant Research (CIBMTR)   (United States)

^c NATIONAL MARROW DONOR PROGRAM   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g Los Angeles County Department of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRIC ACID; IBUPROFEN; PARACETAMOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVERSE OUTCOME; ANOREXIA; APHERESIS; ARTICLE; BACKACHE; BLEEDING; BONE PAIN; CHILL; CLINICAL EVALUATION; COMPARATIVE STUDY; DISEASE SEVERITY; DONOR; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMATOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE REACTION; INSOMNIA; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; OBESITY; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SAFETY; SEX DIFFERENCE; SINGLE DRUG DOSE; SKIN ALLERGY; SYNCOPE; THORAX PAIN; THROMBOCYTOPENIA; VIRUS INFECTION; VOMITING;

EID: 65349145905     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-175323     Document Type: Article

References (30)

1. Craddock C, Szydlo RM, Klein JP, et al. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood. 2000;96:86-90.
2. Karlsson L, Quinlan D, Guo D, et al. Mobilized blood cells vs bone marrow harvest: experience compared in 171 donors with particular reference to pain and fatigue. Bone Marrow Transplant. 2004;33:709-713.
3. Cesaro S, Marson P, Gazzola MV, et al. The use of cytokine-stimulated healthy donors in allogeneic stem cell transplantation. Haematologica. 2002;87:35-41.
4. Anderlini P, Przepiorka D, Lauppe J, et al. Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol. 1997;97:485-487.
5. Pulsipher MA, Levine JE, Hayashi RJ, et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant. 2005;35:361-367.
6. Favre G, Beksac M, Bacigalupo A, et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant. 2003;32:873-880.
7. Grigg AP, Roberts AW, Raunow H, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood. 1995;86:4437-4445.
8. Heldal D, Brinch L, Tjonnfjord G, et al. Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaints. Bone Marrow Transplant. 2002;29:479-486.
9. Rowley SD, Donaldson G, Lilleby K, Bensinger WI, Appelbaum FR. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood. 2001;97:2541-2548.
10. Waller CF, Bertz H, Wenger MK, et al. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant. 1996;18:279-283.
11. Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (lBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant. 2001;27:689-692.
12. Blau lW, Basara N, Lentini G, et al. Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study. Bone MarrowTransplant. 2001;27:27-33.
13. Stroncek DF, Confer DL, Leitman SF. Peripheral blood progenitor cells for HPC transplants involving unrelated donors. Transfusion. 2000;40:731-741.
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
15. Anderlini P, Korbling M, Dale D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997;90:903-908.
16. Anderlini P, Przepiorka D, Champlin R, Korbling M. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood. 1996;88:2819-2825.
17. Tjønnfjord GE, Steen R, Evensen SA, Thorsby E, Egeland T. Characterization of CD34+ peripheral blood cells from healthy adults mobilized by re- combinant human granulocyte colony-stimulating factor. Blood. 1994;84:2795-2801.
18. Dincer AP, Gottschall J, Margolis DA. Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. J Pediatr Hematol Oncol. 2004;26:761-763.
19. Falzetti F, Aversa F, Minelli O, Tabilio A. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet. 1999;353:555.
20. Kröger N, Renges H, Sonnenberg S, et al. Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant. 2002;29:727-730.
21. Pitini V, Ciccolo A, Arrigo C, Aloi G, Micali C, La Torre F. Spontaneous rupture of spleen during periferal blood stem cell mobilization in a patient with breast cancer. Haematologica. 2000;85:559-560.
22. Confer DL. Hematopoietic cell donors. In: Blume KG, Forman SJ, Appelbaum F, eds. Thomas' Hematopoietic Cell Transplantation. 3rd Ed. Oxford, United Kingdom: Blackwell Publishing; 2004:538-549.
23. Donadieu J, Leblanc T, Bader Meunier B, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia: experience of the French Severe Chronic Neutropenia Study Group. Haematologica. 2005;90:45-53.
24. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006;107:4628-4635.
25. Bennett CL, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol. 2006;135:642-650.
26. Anderlini P, Chan FA, Champlin RE, Korbling M, Strom SS. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant. 2002;30:661-663.
27. Sakamaki S, Matsunaga T, Hirayama Y, Kuga T, Niitsu Y. Haematological study of healthy volunteers 5 years after G-CSF. Lancet. 1995;346:1432-1433.
28. Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant. 2000;25:85-89.
29. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer. 2006;46:422-433.
30. Storek J, Dawson MA, Maloney DG. Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting. Blood. 2000;95:2993-2994.